Myovant, Sumitomo Beat Investor Suit Over Skadden Advice
Sumitomo Pharma America Inc. and Myovant Sciences Ltd. have escaped for good a proposed class action alleging the companies' merger was undervalued because the lawyers from Skadden Arps Slate Meagher &...To view the full article, register now.
Already a subscriber? Click here to view full article